{"id":"https://openalex.org/W4319657142","doi":"https://doi.org/10.2174/1568009623666230209121732","title":"Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors","display_name":"Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors","publication_year":2023,"publication_date":"2023-02-09","ids":{"openalex":"https://openalex.org/W4319657142","doi":"https://doi.org/10.2174/1568009623666230209121732","pmid":"https://pubmed.ncbi.nlm.nih.gov/36757037"},"language":"en","primary_location":{"id":"doi:10.2174/1568009623666230209121732","doi":"https://doi.org/10.2174/1568009623666230209121732","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1568009623666230209121732","pdf_url":null,"source":{"id":"https://openalex.org/S26162253","display_name":"Current Cancer Drug Targets","issn_l":"1568-0096","issn":["1568-0096","1873-5576"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Cancer Drug Targets","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014073501","display_name":"Fine Aliyuda","orcid":"https://orcid.org/0000-0002-3249-8638","observed_orcids":["https://orcid.org/0000-0002-3249-8638"]},"institutions":[{"id":"https://openalex.org/I4210104168","display_name":"Medway NHS Foundation Trust","ror":"https://ror.org/01apxt611","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210104168"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Fine Aliyuda","raw_affiliation_strings":["Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK","institution_ids":["https://openalex.org/I4210104168"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059943491","display_name":"Michele Moschetta","orcid":"https://orcid.org/0000-0003-4370-1723","observed_orcids":["https://orcid.org/0000-0003-4370-1723"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Michele Moschetta","raw_affiliation_strings":["Novartis Institutes for BioMedical\nResearch, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for BioMedical\nResearch, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084117294","display_name":"Aruni Ghose","orcid":"https://orcid.org/0000-0001-8332-8033","observed_orcids":["https://orcid.org/0000-0001-8332-8033"]},"institutions":[{"id":"https://openalex.org/I1307195382","display_name":"St Bartholomew's Hospital","ror":"https://ror.org/00nh9x179","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1307195382","https://openalex.org/I225661044"]},{"id":"https://openalex.org/I225661044","display_name":"Barts Health NHS Trust","ror":"https://ror.org/00b31g692","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044"]},{"id":"https://openalex.org/I4210104168","display_name":"Medway NHS Foundation Trust","ror":"https://ror.org/01apxt611","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210104168"]},{"id":"https://openalex.org/I4210108939","display_name":"Mount Vernon Cancer Centre","ror":"https://ror.org/01wwv4x50","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210108939","https://openalex.org/I4210122718"]},{"id":"https://openalex.org/I4210122718","display_name":"East and North Hertfordshire NHS Trust","ror":"https://ror.org/02ryc4y44","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210122718"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Aruni Ghose","raw_affiliation_strings":["Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew\u2019s\nHospital, Barts Health NHS Trust, London, UK","Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK","Department of Medical Oncology, Mount Vernon Cancer Centre, East\nand North Hertfordshire NHS Trust, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew\u2019s\nHospital, Barts Health NHS Trust, London, UK","institution_ids":["https://openalex.org/I1307195382","https://openalex.org/I225661044"]},{"raw_affiliation_string":"Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK","institution_ids":["https://openalex.org/I4210104168"]},{"raw_affiliation_string":"Department of Medical Oncology, Mount Vernon Cancer Centre, East\nand North Hertfordshire NHS Trust, London, UK","institution_ids":["https://openalex.org/I4210108939","https://openalex.org/I4210122718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050012877","display_name":"Kathrine S Rallis","orcid":"https://orcid.org/0000-0003-1011-3220","observed_orcids":["https://orcid.org/0000-0003-1011-3220"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Kathrine Sofia Rallis","raw_affiliation_strings":["Cancer Research Institute, Beth Israel Deaconess Medical Center,\nHarvard Medical School, Boston, USA","Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary\nUniversity of London, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research Institute, Beth Israel Deaconess Medical Center,\nHarvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary\nUniversity of London, London, UK","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405264518"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016163128","display_name":"Matin Sheriff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104168","display_name":"Medway NHS Foundation Trust","ror":"https://ror.org/01apxt611","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210104168"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matin Sheriff","raw_affiliation_strings":["Department of Urology, Medway NHS Foundation Trust, Windmill Road, ME7\n5NY, Gillingham, Kent, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Medway NHS Foundation Trust, Windmill Road, ME7\n5NY, Gillingham, Kent, UK","institution_ids":["https://openalex.org/I4210104168"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111042630","display_name":"Elisabet Sanchez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104168","display_name":"Medway NHS Foundation Trust","ror":"https://ror.org/01apxt611","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210104168"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Elisabet Sanchez","raw_affiliation_strings":["Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK","institution_ids":["https://openalex.org/I4210104168"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029091749","display_name":"Elie Rassy","orcid":"https://orcid.org/0000-0002-7906-0991","observed_orcids":["https://orcid.org/0000-0002-7906-0991"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Elie Rassy","raw_affiliation_strings":["Department of Medical Oncology, Gustave Roussy Institute, 94805, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Gustave Roussy Institute, 94805, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057565228","display_name":"Stergios Boussios","orcid":"https://orcid.org/0000-0002-2512-6131","observed_orcids":["https://orcid.org/0000-0002-2512-6131"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210104168","display_name":"Medway NHS Foundation Trust","ror":"https://ror.org/01apxt611","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210104168"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Stergios Boussios","raw_affiliation_strings":["AELIA Organization, 9th Km Thessaloniki - Thermi, Thessaloniki, 57001, Greece","Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK","Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, London,\nUK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AELIA Organization, 9th Km Thessaloniki - Thermi, Thessaloniki, 57001, Greece","institution_ids":[]},{"raw_affiliation_string":"Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK","institution_ids":["https://openalex.org/I4210104168"]},{"raw_affiliation_string":"Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, London,\nUK","institution_ids":["https://openalex.org/I183935753"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":12,"corresponding_author_ids":["https://openalex.org/A5057565228"],"corresponding_institution_ids":["https://openalex.org/I183935753","https://openalex.org/I4210104168"],"apc_list":null,"apc_paid":null,"fwci":13.2915,"has_fulltext":false,"cited_by_count":105,"citation_normalized_percentile":{"value":0.99314712,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"23","issue":"6","first_page":"433","last_page":"446"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.6060000061988831,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.6060000061988831,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.3921000063419342,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10390","display_name":"Ovarian function and disorders","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":1.0},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8629999756813049},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.8889999985694885},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9710000157356262},{"id":"https://openalex.org/keywords/angiogenesis","display_name":"angiogenesis","score":0.9179999828338623},{"id":"https://openalex.org/keywords/pi3k-akt-mtor-pathway","display_name":"PI3K/AKT/mTOR pathway","score":0.9549999833106995},{"id":"https://openalex.org/keywords/microrna","display_name":"microRNA","score":0.8659999966621399},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.843999981880188},{"id":"https://openalex.org/keywords/molecular-heterogeneity","display_name":"molecular heterogeneity","score":0.6830000281333923},{"id":"https://openalex.org/keywords/growth-factor-signaling","display_name":"growth factor signaling","score":0.4399999976158142}],"concepts":[{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.8080381155014038},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.6570116281509399},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5649150609970093},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5508909821510315},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.5326340198516846},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5147750377655029},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.5102887153625488},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.49839258193969727},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3757936954498291},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3416026830673218},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29243940114974976},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.28170251846313477},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.23818767070770264},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2211170196533203},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000067856","descriptor_name":"Poly(ADP-ribose) Polymerase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D011065","descriptor_name":"Poly(ADP-ribose) Polymerases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.2174/1568009623666230209121732","doi":"https://doi.org/10.2174/1568009623666230209121732","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1568009623666230209121732","pdf_url":null,"source":{"id":"https://openalex.org/S26162253","display_name":"Current Cancer Drug Targets","issn_l":"1568-0096","issn":["1568-0096","1873-5576"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Cancer Drug Targets","raw_type":"journal-article"},{"id":"pmid:36757037","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36757037","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current cancer drug targets","raw_type":"Journal Article"},{"id":"pmh:oai:HAL:inserm-04573160v1","doi":null,"is_oa":false,"landing_page_url":"https://inserm.hal.science/inserm-04573160","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Current Cancer Drug Targets, 2023, 23 (6), pp.433 - 446. ⟨10.2174/1568009623666230209121732⟩","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":106,"referenced_works":["https://openalex.org/W1793338775","https://openalex.org/W1967342065","https://openalex.org/W1968263552","https://openalex.org/W1974028385","https://openalex.org/W1983790923","https://openalex.org/W1988878042","https://openalex.org/W1990788224","https://openalex.org/W2002064506","https://openalex.org/W2008908425","https://openalex.org/W2014689880","https://openalex.org/W2040468807","https://openalex.org/W2054001958","https://openalex.org/W2067114310","https://openalex.org/W2068675926","https://openalex.org/W2108947370","https://openalex.org/W2110820382","https://openalex.org/W2113122060","https://openalex.org/W2114553148","https://openalex.org/W2119646041","https://openalex.org/W2121741947","https://openalex.org/W2127447993","https://openalex.org/W2130160735","https://openalex.org/W2131232783","https://openalex.org/W2133537644","https://openalex.org/W2135947389","https://openalex.org/W2137074525","https://openalex.org/W2141125222","https://openalex.org/W2141520074","https://openalex.org/W2143874982","https://openalex.org/W2149296859","https://openalex.org/W2149891355","https://openalex.org/W2152111447","https://openalex.org/W2154056804","https://openalex.org/W2156198002","https://openalex.org/W2159089112","https://openalex.org/W2204493619","https://openalex.org/W2311462071","https://openalex.org/W2557860064","https://openalex.org/W2558976494","https://openalex.org/W2560183544","https://openalex.org/W2560512460","https://openalex.org/W2563450347","https://openalex.org/W2583998975","https://openalex.org/W2592655542","https://openalex.org/W2593027991","https://openalex.org/W2594404528","https://openalex.org/W2605456582","https://openalex.org/W2609464715","https://openalex.org/W2616559237","https://openalex.org/W2619886251","https://openalex.org/W2626153771","https://openalex.org/W2718759517","https://openalex.org/W2743779948","https://openalex.org/W2766430492","https://openalex.org/W2771491442","https://openalex.org/W2771566635","https://openalex.org/W2772288154","https://openalex.org/W2772815803","https://openalex.org/W2791742117","https://openalex.org/W2795054625","https://openalex.org/W2905630942","https://openalex.org/W2911528643","https://openalex.org/W2912893085","https://openalex.org/W2913578326","https://openalex.org/W2934498937","https://openalex.org/W2942161662","https://openalex.org/W2946351532","https://openalex.org/W2951714360","https://openalex.org/W2954370385","https://openalex.org/W2965546441","https://openalex.org/W2972484989","https://openalex.org/W2981585441","https://openalex.org/W3002899364","https://openalex.org/W3013350468","https://openalex.org/W3015444296","https://openalex.org/W3022053420","https://openalex.org/W3023274953","https://openalex.org/W3026312014","https://openalex.org/W3026977895","https://openalex.org/W3036505025","https://openalex.org/W3037087593","https://openalex.org/W3040019917","https://openalex.org/W3040422500","https://openalex.org/W3046361694","https://openalex.org/W3049110644","https://openalex.org/W3112267132","https://openalex.org/W3115638890","https://openalex.org/W3128646645","https://openalex.org/W3139410613","https://openalex.org/W3181245501","https://openalex.org/W3181587133","https://openalex.org/W3185294130","https://openalex.org/W3200255422","https://openalex.org/W3201437718","https://openalex.org/W3207702660","https://openalex.org/W4205371966","https://openalex.org/W4211083170","https://openalex.org/W4229453381","https://openalex.org/W4230886463","https://openalex.org/W4233498657","https://openalex.org/W4237473415","https://openalex.org/W4238843936","https://openalex.org/W4283797984","https://openalex.org/W4285595457","https://openalex.org/W4291011829","https://openalex.org/W4295087018"],"related_works":["https://openalex.org/W3149732999","https://openalex.org/W4380605757","https://openalex.org/W2057087136","https://openalex.org/W2319296864","https://openalex.org/W2058783279","https://openalex.org/W2120122518","https://openalex.org/W2074066657","https://openalex.org/W2990730352","https://openalex.org/W7131349727","https://openalex.org/W1944279639"],"abstract_inverted_index":{"Ovarian":[0,25],"cancer":[1,26,92,165],"has":[2,20],"become":[3,136],"the":[4,73,96,116,140,151,158],"largest":[5],"cause":[6],"of":[7,43,47,66,83,98,120,145,160],"gynaecological":[8],"cancer-related":[9],"mortality.":[10],"It":[11],"is":[12,27],"typically":[13],"diagnosed":[14],"at":[15,93],"a":[16,28,41,44],"late":[17],"stage":[18],"and":[19,53,72,85,142,154,166],"no":[21],"effective":[22,87],"screening":[23],"strategy.":[24],"highly":[29],"heterogeneous":[30],"disease":[31],"that":[32],"can":[33],"be":[34],"subdivided":[35],"into":[36],"several":[37,64],"molecular":[38,48],"subsets.":[39],"As":[40],"result":[42],"greater":[45],"understanding":[46],"pathways":[49,108,162],"involved":[50],"in":[51,63,130,163],"carcinogenesis":[52],"tumor":[54],"growth,":[55],"targeted":[56,88,172],"agents":[57],"have":[58,134],"been":[59],"approved":[60,84],"or":[61,127],"are":[62,80,109,124,128],"stages":[65],"development.":[67],"Poly(ADP-ribose)":[68],"polymerase":[69],"(PARP)":[70],"inhibitors":[71,102],"anti-vascular":[74],"endothelial":[75],"growth":[76],"factor":[77],"(VEGF)-A":[78],"antibodies":[79],"two":[81],"types":[82],"most":[86],"drugs":[89],"for":[90,139],"ovarian":[91,146,164],"present.":[94],"With":[95],"success":[97],"bevacizumab,":[99],"tyrosine":[100],"kinase":[101],"which":[103],"could":[104],"target":[105,119],"alternate":[106],"angiogenic":[107],"being":[110,125],"studied.":[111],"Furthermore,":[112],"many":[113],"treatments":[114,173],"targeting":[115,159],"PI3-kinase":[117],"(PI3K)/AKT/mammalian":[118],"rapamycin":[121],"(mTOR)":[122],"pathways,":[123],"developed":[126],"already":[129],"clinical":[131,143,155],"studies.":[132],"MicroRNAs":[133],"also":[135],"novel":[137],"biomarkers":[138],"therapy":[141],"diagnosis":[144],"cancer.":[147],"This":[148],"manuscript":[149],"reviews":[150],"molecular,":[152],"preclinical":[153],"evidence":[156],"supporting":[157],"growth-dependent":[161],"assesses":[167],"current":[168],"data":[169],"related":[170],"to":[171],"beyond":[174],"PARP":[175],"inhibitors.":[176]},"counts_by_year":[{"year":2026,"cited_by_count":10},{"year":2025,"cited_by_count":34},{"year":2024,"cited_by_count":56},{"year":2023,"cited_by_count":5}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2023-02-10T00:00:00"}